BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $111 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $56.91 +2.25%
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $111.00 (from $107.00) while maintaining a Outperform rating.
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $94 at Oppenheimer
- SGHC Limited (SGHC) PT Lowered to $16 at StoneX
- TETRA Technologies Inc. (TTI) PT Lowered to $11 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
